



HAL
open science

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs

Meryl Roudaut, Salam Idriss, Amandine Caillaud, Aurore Girardeau, Antoine Rimbart, Benoite Champon, Amandine David, Antoine Lévêque, Lucie Arnaud, Matthieu Pichelin, et al.

► **To cite this version:**

Meryl Roudaut, Salam Idriss, Amandine Caillaud, Aurore Girardeau, Antoine Rimbart, et al. PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. *Stem Cell Reports*, 2021, <10.1016/j.stemcr.2021.10.004>. <hal-03451184>

HAL Id: hal-03451184

<https://hal.science/hal-03451184v1>

Submitted on 8 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

1 **PCSK9 regulates the NODAL signaling pathway**
2 **and cellular proliferation in hiPSCs**

3

4 **Running title:** PCSK9 function in hiPSCs

5

6 Meryl Roudaut^{1,2#}, Salam Idriss^{1,3#}, Amandine Caillaud¹, Aurore Girardeau¹, Antoine
7 Rimbert¹, Benoite Champon¹, Amandine David¹, Antoine Lévêque¹, Lucie Arnaud¹, Matthieu
8 Pichelin^{1,4}, Xavier Prieur¹, Annik Prat⁵, Nabil G Seidah⁵, Kazem Zibara³, Cedric Le May¹,
9 Bertrand Cariou^{1,4§,*}, Karim Si-Tayeb^{1,§,*}

10

11 1. Université de Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France.

12 2. HCS Pharma, Lille, France

13 3. ER045 - Laboratory of Stem Cells: Maintenance, Differentiation and Pathology, Biology
14 Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon

15 4. Université de Nantes, CHU Nantes, CNRS, INSERM, l'institut du thorax, F-44000 Nantes,
16 France.

17 5. University of Montreal, Montreal, QC, Canada

18

19 # These authors contributed equally.

20 § Co-senior author.

21

22 * Corresponding authors:

23 bertrand.cariou@univ-nantes.fr

24 karim.si-tayeb@univ-nantes.fr

25

26

1 **SUMMARY**

2 Proprotein convertase subtilisin kexin type 9 (PCSK9) is a key regulator of LDL cholesterol
3 metabolism and the target of lipid-lowering drugs. PCSK9 is mainly expressed in hepatocytes.
4 Here, we show that PCSK9 is highly expressed in undifferentiated human induced pluripotent
5 stem cells (hiPSCs). PCSK9 inhibition in hiPSCs with the use of shRNA, CRISPR/cas9-
6 mediated knockout or endogenous *PCSK9* loss-of-function mutation R104C/V114A unveiled
7 its new role as a potential cell cycle regulator through the NODAL signaling pathway. In fact,
8 PCSK9 inhibition leads to a decrease of SMAD2 phosphorylation and hiPSCs proliferation.
9 Conversely, PCSK9 overexpression stimulates hiPSCs proliferation. PCSK9 can interfere
10 with the NODAL pathway by regulating the expression of its endogenous inhibitor DACT2,
11 which is involved in the TGFβ-R1 lysosomal degradation. Using different PCSK9 constructs
12 we show that PCSK9 interacts with DACT2 through its CHRD domain. Altogether these data
13 highlight a new role of PCSK9 in cellular proliferation and development.

14

1 **HIGHLIGHTS**

- 2 • PCSK9 is highly expressed in undifferentiated hiPSCs
- 3 • PCSK9 regulates hiPS cell proliferation
- 4 • PCSK9 controls NODAL signaling and SMAD2 phosphorylation in hiPSCs
- 5 • PCSK9 controls TGF β -R1 expression potentially through its interaction with DACT2

1 INTRODUCTION

2 Proprotein convertase subtilisin kexin type 9 (PCSK9) is a master regulator of
3 cholesterol homeostasis (for review, see (Seidah et al., 2017; Stoekenbroek et al., 2018)).
4 PCSK9 was initially discovered as the third gene of familial hypercholesterolemia (FH), an
5 autosomal co-dominant disorder that leads to premature atherosclerotic cardiovascular disease
6 (Abifadel et al., 2003). While *PCSK9* gain-of-function (GOF) mutations cause FH, *PCSK9*
7 loss-of-function (LOF) variants are conversely associated with reduced low-density
8 lipoprotein (LDL) cholesterol levels and coronary heart disease (Cohen et al., 2006).
9 Mendelian randomization studies further validate the concept that PCSK9 inhibition reduces
10 cardiovascular events (Ference et al., 2016), leading to the development of PCSK9 inhibitors
11 to manage cardiovascular disease in clinical practice (Preiss et al., 2020).

12 The canonical action of PCSK9 is to promote the downregulation of LDL receptor
13 (LDLR) expression (Maxwell and Breslow, 2004). PCSK9 is mainly expressed in the
14 hepatocyte, where it undergoes in the endoplasmic reticulum an autocatalytic cleavage
15 between its pro and catalytic domains (Benjannet et al., 2004). One surprising key feature that
16 distinguishes PCSK9 from the other proprotein convertases is that its prodomain is not
17 released after its cleavage and remains closely bound in the catalytic site, leading to a secreted
18 inactive protease (Seidah et al., 2003). After its cleavage, PCSK9 is secreted into the
19 circulation, binds to the epidermal growth factor precursor homology domain A (EGF-A)
20 extra-cellular domain of the LDLR and is internalized together with the receptor. The
21 presence of the adaptor protein (LDLRAP1) that interacts intracellularly with the LDLR tail is
22 required to allow the internalization of the LDLR-PCSK9 complex. Inside the cell, the
23 binding of PCSK9 to the LDLR alters its acidic pH induced conformational change, which
24 prevents normal recycling of the LDLR and instead targets the LDLR/PCSK9 complex to
25 lysosomal degradation (Zhang et al., 2007). All the mechanistic steps by which this
26 intracellular trafficking of the LDLR-PCSK9 complex takes place have not yet been fully
27 elucidated (Seidah et al., 2017).

28 Beyond this so-called extracellular route of action of PCSK9, several data suggest that
29 PCSK9 can act on the LDLR directly *via* an intracellular Golgi-lysosome route (Poirier et al.,
30 2009). The existence of an intracellular route was supported by the fact that PCSK9 and the
31 LDLR can interact very early inside the cell in the secretory pathway and more importantly
32 that PCSK9 maintains its ability to promote LDLR degradation in cells devoid of LDLRAP1
33 protein (Poirier et al., 2009). PCSK9 inhibitors, alirocumab and evolocumab, are human
34 monoclonal antibodies that interfere with the extra-cellular pathway by neutralizing

1 circulating PCSK9 and thus preventing its binding to the LDLR. Alternatively, inclisiran, a
2 small interfering RNA which inhibits hepatic synthesis of PCSK9, impacts both extra-cellular
3 and intra-cellular PCSK9 signaling pathways (Catapano et al., 2020).

4 We previously published that urine-sample-derived human induced pluripotent stem
5 cells (hiPSCs) differentiated into hepatocyte-like cells (HLCs) is a relevant model to study the
6 impact of *PCSK9* gain-of-function (GOF) and loss-of-function (LOF) mutations on
7 cholesterol metabolism regulation (Si-Tayeb et al., 2016). During the validation process of
8 our hiPSCs model, we made the intriguing observation that PCSK9 was highly expressed in
9 undifferentiated hiPSCs, as previously noted (Assou et al., 2007; Calloni et al., 2013;
10 Tsuneyoshi et al., 2008).

11 The aim of the present study is to decipher the function of PCSK9 in hiPSCs. By using
12 both hiPSCs derived from patients with *PCSK9* LOF mutations and control hiPSCs with
13 PCSK9 silencing, knockout or overexpression, we showed that PCSK9 interferes with the
14 TGF β -NODAL signaling pathway, a major actor in stem cells self-renewal, differentiation
15 and proliferation (for review, see (Pauklin and Vallier, 2015)).

16

1 RESULTS

2 PCSK9 is highly expressed in undifferentiated hiPSCs

3 In order to gain further knowledge on the role of PCSK9 during hiPSCs hepatic
4 differentiation, we monitored PCSK9 gene expression at each day throughout the procedure.
5 As shown in **Figure 1A**, PCSK9 mRNA expression varies during hiPSCs differentiation.
6 While PCSK9 expression has been already confirmed in HLCs (Si-Tayeb et al., 2016), we
7 showed a stronger PCSK9 expression in the early stages of differentiation, such as the
8 definitive endoderm and during its hepatic specification. Thereafter, hepatic differentiation
9 upon HGF treatment (Days 11 to 15) induced a lower PCSK9 expression before a rebound
10 during the final days of HLCs differentiation. In accordance with mRNA expression, PCSK9
11 protein expression (mature form (60kDa) and cleaved prodomain (15kDa)) was significantly
12 higher in undifferentiated hiPSCs than in hepatic progenitors (**Figure 1B**). Finally, PCSK9
13 protein secretion in the cell culture medium measured by ELISA assay paralleled the PCSK9
14 mRNA and protein variations (**Figure 1C**). Notably, the level of secreted PCSK9 was much
15 higher in hiPSCs than in HLCs. Altogether these data demonstrate that undifferentiated
16 hiPSCs express and secrete PCSK9 at significant level.

17

18 PCSK9 inhibition modulates the NODAL signaling pathway and cell proliferation in 19 hiPSCs

20 In order to investigate the functional role of PCSK9 in this newly described
21 environment, we silenced PCSK9 in hiPSCs using specific shRNA (originally from K3 hiPS
22 cell line - **Supplemental Table 1**) and performed a transcriptomic analysis (DNA-chip
23 Agilent). From the list of differentially expressed genes between iPSCs-shPCSK9 vs. iPSCs-
24 shCtrl (**Supplemental Table 2**) we screened for overrepresented biological processes using
25 Gene Ontology (GO) terms in genes downregulated together with PCSK9 in iPSCs-shPCSK9
26 vs. iPSCs-shCtrl. Significant GO biological processes are mainly related to metabolic,
27 biosynthetic and developmental processes (**Supplemental Table 3**). More specifically, the
28 top differentially expressed genes include *PCSK9* itself, with more than 90% inhibition,
29 *NODAL* and *NODAL* downstream pathway gene target such as *LEFTY2*. RT-Q-PCR analysis
30 further confirmed that *PCSK9*, *NODAL* and *LEFTY1* were significantly down-regulated in
31 PCSK9 silenced hiPSCs (**Figure 2A**). Despite a trend, PCSK9 silencing did not significantly
32 alter *LDLR* mRNA levels (**Figure 2A**). In addition, two other targets of the NODAL signaling
33 pathway, *OCT4* and *NANOG* showed a decreased gene expression. While both *OCT3* and
34 *NANOG* are pluripotent transcription factors expressed also in the mesendoderm, we

1 monitored the expression of a third pluripotent transcription factor subsequently expressed
2 during ectoderm differentiation, *SOX2*, which was not affected by PCSK9 silencing. In
3 accordance with a functional effect of NODAL pathway gene expression regulation, we
4 observed that the modulation of PCSK9 gene expression affects hiPSCs proliferation. Indeed,
5 the cellular growth curve was significantly reduced in hiPSCs silenced for PCSK9 compared
6 to hiPSCs control (**Figure 2B**).

7 To further study the impact of PCSK9 on the NODAL signaling pathway in
8 undifferentiated cells, we generated two cellular models that were studied side by side. We
9 first generated a PCSK9 knock-out (KO) hiPSCs (PCSK9-KO) with a CRISPR/Cas9 system
10 (from hERG control cell line- Supplemental **Table 1**). We also generated a stable hiPS cell-
11 line overexpressing PCSK9 (PCSK9-FULL) through the integration of PCSK9 at the AAVS1
12 locus (from hERG control cell line). Western blot analysis confirmed that PCSK9 protein
13 expression was totally lost in PCSK9-KO hiPSCs and strongly increased in PCSK9-FULL
14 hiPSCs (**Figure 3A**). Then, we assessed the cell proliferation of PCSK9-KO and PCSK9-
15 FULL hiPSCs (**Figure 3B**). In line with the previous results, while PCSK9-KO hiPSCs
16 present a significantly reduced cell growth, the proliferation of PCSK9-FULL hiPSCs was
17 significantly increased. Next, we investigated the phosphorylation state of the NODAL
18 signaling pathway mediator, SMAD2. As shown in **Figure 3C**, SMAD2 phosphorylation
19 status was reduced in PCSK9-KO hiPSCs, while it was increased in PCSK9-FULL hiPSCs,
20 further validating the hypothesis of an impact of PCSK9 on the NODAL signaling pathway.

21 In order to further strengthen our previous observations and validate them in patients'
22 material with non-genetically engineered hiPSCs, we generated and studied hiPSCs of a
23 patient carrying the PCSK9 LOF mutations R104C/V114A. This patient presented with
24 genetically low levels of LDL-C (*i.e.* familial hypobetalipoproteinemia) and an absence of
25 liver-derived circulating PCSK9 (Cariou et al., 2009). Previous *in vitro* investigations
26 suggested that R104C/V114A mutations prevented PCSK9 auto-cleavage, its subsequent
27 secretion and acted as a dominant negative mutant (Cariou et al., 2009). Indeed, we observed
28 that PCSK9 auto-cleavage was drastically diminished in R104C/V114A hiPSCs, resulting in a
29 higher proportion of uncleaved non-mature form of PCSK9 (**Figure 4A**). In accordance with
30 PCSK9-KO hiPSCs results, the cellular growth and the phosphorylated form of SMAD2,
31 were decreased in hiPSCs R104C/V114A compared to the control hiPSCs (**Figure 4B and**
32 **C**). Finally, we monitored the effect of the R104C/V114A LOF mutations on the overall
33 TGF β signaling pathway upon the introduction of a TGF β -gene reporter through luciferase
34 activity in the control and patient-derived hiPSC lines (Huang et al., 2011). As depicted in

1 **Figure 4D**, PCSK9 R104C/V114A hiPSCs present with a drastic reduction of the luciferase
2 activity when compared to controls.

3 Altogether, our data indicate that PCSK9 inhibition, due to either CRISPR-mediated
4 knockout or LOF mutations, decreases the NODAL signaling pathway.

5

6 **PCSK9 deficiency decreases TGF β R1 content in hiPSCs potentially through an up-** 7 **regulation of DACT2**

8 To further precise the mechanism of action of PCSK9 on the NODAL signaling
9 pathway, we added the recombinant wild-type PCSK9 (rPCSK9-WT) or an overactive
10 recombinant form of PCSK9 (rPCSK9-D374Y) in control hiPSCs culture medium over 24h.
11 The addition of rPCSK9-WT or rPCSK9-D374Y in the medium did not affect the SMAD2
12 phosphorylation status (**Supplemental Figure 1**), suggesting that PCSK9 interferes with the
13 NODAL pathway intracellularly rather than extracellularly.

14 Then, we tried to overcome the downregulation of NODAL signaling associated to
15 PCSK9 deficiency by adding recombinant NODAL protein (up to 200 ng/mL during 2 hours)
16 in the culture medium of either control or PCSK9 R104C/V114A hiPSCs. In contrast to what
17 was observed in control hiPSCs, NODAL was unable to induce SMAD2 phosphorylation in
18 R104C/V114A hiPSCs (**Supplemental Figure 2**), suggesting that PCSK9 is required for
19 NODAL activity in hiPSCs.

20 Based on these results, we hypothesized that PCSK9 might directly interfere with
21 NODAL signaling at the TGF β receptor subunit 1 (TGF β R1) level. We measured the
22 abundance of TGF β R1 at the cell surface in different hiPSC lines using a biotinylation assay.
23 While the TGF β R1 content was consistently lowered in both PCSK9-KO and R104C/V114A
24 hiPSCs compared to control hiPSCs, no significant difference was detected in PCSK9-FULL
25 hiPSCs (**Figure 5**).

26 TGF β R1 has been described as a target of the Dishevelled Antagonist of β -Catenin 2
27 (DACT2), which is located in late endosomes and induces TGF β R1 lysosomal degradation
28 (Zhang et al., 2004). Through western blot analysis, we found that the expression of DACT2
29 (isoform: ENSP00000476434, Q5SW24; 40 kDa) was significantly increased in PCSK9-KO
30 hiPSCs as well as in R104C/V114A hiPSCs when compared to controls (**Figure 6A & B**). In
31 contrast, we did not observe changes in DACT2 protein expression in PCSK9-FULL hiPSCs
32 (**Figure 6C**). In order to verify whether PCSK9 could interact intracellularly with DACT2 in
33 hiPSCs we generated several hiPSC lines expressing either: i) the V5-tagged-PCSK9-full-
34 protein (FL-PCSK9 hiPSCs), ii) the V5-tagged-PCSK9-protein lacking the prodomain and

1 catalytic domain (CHRD hiPSCs) or iii) the V5-tagged-PCSK9-protein lacking (L455X
2 hiPSCs) (**Figure 7A**). Upon V5-mediated PCSK9 pull-down, we found that the DACT2
3 40kDa isoform was co-immunoprecipitated with V5-PCSK9 in FL-PCSK9 hiPSCs (**Figure**
4 **7B**). Moreover, while DACT2 was also detected in CHRD hiPSCs, it was lost with the
5 L455X-construct, suggesting that PCSK9 interacts with DACT2 *via* its CHRD domain.

6 Taken together, these data suggest that intra-cellular PCSK9 may modulate TGF β R1
7 signaling pathway by regulating DACT2 expression.

8

9

10

11

12

13

14

1 **DISCUSSION**

2 In the present study, we report for the first time that PCSK9 is expressed at a high
3 level in hiPSCs. While PCSK9 expression is maximal in the undifferentiated state, it
4 decreases during the hepatic differentiation program before a final rebound in the late HLCs
5 differentiation steps. From a functional point of view, we showed that PCSK9 controls the
6 cellular proliferation of hiPSCs. Regarding the molecular mechanisms, we demonstrated that
7 PCSK9 interferes with the NODAL/SMAD2 signaling pathway at least by interacting with
8 DACT2, an inhibitor of TGF β R1. In our working model, PCSK9 leads to a degradation of
9 DACT2, thereby stimulating the NODAL pathway and the cellular proliferation of hiPSCs.

10

11 Importantly, our work opens novel perspectives in the field of PCSK9 biology by
12 identifying: i) a novel cellular environment for PCSK9 action, which is not restricted to
13 mature hepatocytes; ii) a novel function for PCSK9 - the regulation of hiPSCs proliferation
14 which is independent of the LDLR pathway; and iii) a potential novel PCSK9 binding partner
15 – DACT2.

16

17 While PCSK9 is mainly expressed in mature hepatocytes, it is expressed in many
18 tissues and cells (Cariou et al., 2015; Seidah et al., 2003). It should be reminded here that
19 PCSK9 was initially cloned in primary cerebellar neurons under apoptotic stimulus (Seidah et
20 al., 2003). In order to gain insights on the potential new functions of PCSK9 in hiPSCs, we
21 performed unbiased transcriptomic approaches after manipulating PCSK9 gene expression.
22 Interestingly, the NODAL pathway (*i.e* NODAL itself and its target genes such as LEFTY1
23 and 2) appears significantly downregulated by silencing of PCSK9. We further confirmed that
24 manipulating PCSK9 expression consistently affects SMAD2 phosphorylation status, that we
25 used as a readout of the NODAL signaling pathway. Of functional relevance, we
26 demonstrated by using complementary models (PCSK9 KO and PCSK9 R104C/V114A LOF
27 mutant) that PCSK9 deficiency in hiPSCs is associated with a reduced cell proliferation.
28 Conversely, PCSK9 overexpression in hiPSCs led to both increased NODAL signaling and
29 cell proliferation.

30

31 From a mechanistic point of view, we first assessed whether PCSK9 interfere with
32 NODAL signaling in an intra-cellular or extra-cellular manner. Our data indicate that 24
33 hours exposure to extracellular recombinant PCSK9 has no effect on SMAD2
34 phosphorylation, suggesting that PCSK9 may act on TGF β R1 and its downstream signaling
pathway mostly through an intracellular effect. In addition, we showed that the addition of

1 recombinant NODAL did not restore SMAD2 phosphorylation in PCSK9-deficient hiPSCs.
2 Although we cannot exclude the hypothesis that PCSK9 is necessary for the signaling action
3 of NODAL *per se*, our data suggest that PCSK9 instead interfere with the abundance of
4 TGF β R1 at the cell surface. The decreased TGF β R1 expression observed in the context of
5 PCSK9 deficiency could explain the reduced NODAL signaling and its resistance to
6 recombinant NODAL treatment.

7 Therefore, we sought for intracellular regulator of TGF β R1. The disheveled
8 antagonist of β -catenin (DACT) family has been described as scaffold proteins involved in
9 cell signaling regulation (Cheyette et al., 2002; Su et al., 2007; Zhang et al., 2004). While
10 DACT1 mostly regulate the Wnt signaling pathways through disheveled lysosomal
11 degradation (Cheyette et al., 2002; Su et al., 2007; Zhang et al., 2004), DACT2 has been
12 described as an inhibitor of the NODAL receptor in zebrafish (Zhang et al., 2004) by binding
13 and targeting it to lysosomal degradation. Su et al. have verified this mechanism in
14 mammalian cells (Su et al., 2007).

15 Based on these observations, we considered DACT2 as a potential target of PCSK9
16 and studied its content at the protein level in our different hiPS cell lines. Importantly, we
17 confirmed that the silencing or inhibition of PCSK9 is associated with an increased DACT2
18 protein content, which is in line with the reduced TGF β R1 expression at the plasma
19 membrane. Although PCSK9 overexpression induced SMAD2 phosphorylation and in a
20 lesser extent cell proliferation, we failed to detect a significant decrease in DACT2 and
21 subsequent increase in TGF β R1 expression. The reason for this discrepancy remains unclear
22 but can be due to non-physiological stoichiometric changes related to massive PCSK9
23 overexpression.

24 Finally, to highlight the potential interaction between PCSK9 and DACT2 we
25 conducted several co-immunoprecipitation experiments and were able to co-
26 immunoprecipitate PCSK9 and DACT2 in undifferentiated hiPSCs. Using truncated forms of
27 PCSK9 stably overexpressed in hiPSCs, we showed that the Cys-His-rich domain (CHRD)
28 was mainly involved in this interaction. The same domain is involved in the interaction
29 between PCSK9 and the LDLR before their trafficking to the lysosomal pathway (Nassoury et
30 al., 2007). In the light of our results, additional experiments remain to be conducted in order
31 to establish whether this interaction is direct or indirect.

32 Our findings open new interesting perspectives for PCSK9 biology in at least two
33 fields of research: development and cancer.

1 NODAL is involved in embryonic stem (ES) cells pluripotency maintenance in mouse
2 and human (Vallier et al., 2009) and crucial for their differentiation (Chng et al., 2010). It is
3 therefore conceivable that PCSK9 contributes to pluripotent stem cell regulatory mechanisms
4 by stimulating the NODAL pathway. Of note, the NODAL function on ES cells seems to be
5 species-specific, with no similar effect in mouse compared to human ES cells (James et al.,
6 2005). This observation can be related to the absence of developmental effect of *Pcsk9*
7 deficiency in mice (Rashid et al., 2005). In contrast, there are several arguments for a
8 potential role for PCSK9 in human development. Firstly, it is intriguing that only very few
9 patients were described with LOF mutations in both alleles of *PCSK9* and virtually none with
10 a complete PCSK9 deficiency have been identified world-wide (Cariou et al., 2009; Zhao et
11 al., 2006). Secondly, PCSK9 has been suggested to be potentially involved in the
12 pathogenesis of neural tube defects (NTDs), due to an association between maternal plasma
13 PCSK9 levels and fetal NTDs risk (An et al., 2015). This observation is reinforced by the
14 findings that NODAL and DACT2 have been shown to be involved in the control of
15 neurulation (Gonsar et al., 2016) and the delamination of neural crest cells (Rabadán et al.,
16 2016) respectively.

17 Although the NODAL pathway is almost not operational after the period of embryonic
18 development, several studies have highlighted an upregulation of NODAL activity in many
19 human cancers. For instance, increased expression of NODAL has been shown to be
20 correlated with disease progression in malignant melanoma (Topczewska et al., 2006). It is
21 intriguing to note that PCSK9 deficiency reduces melanoma metastasis in mouse livers (Sun
22 et al., 2012). While one mechanistic hypothesis for the link between PCSK9 and cancer
23 progression is the modulation of cholesterol supply to the tumor (Huang et al., 2016), a recent
24 paper described PCSK9 as a regulator of the major histocompatibility protein class I (MHCI)
25 recycling by promoting its relocation and degradation in the lysosome (Liu et al., 2020). This
26 result identified PCSK9 as a promising strategy in cancer immunotherapy (Almeida et al.,
27 2021). Our data suggest that PCSK9 may directly regulates cell proliferation, potentially
28 through a modulation of NODAL signaling. Thus, it would be interesting to assess whether
29 PCSK9 can also regulate NODAL pathway and cell proliferation in the context of cancer.

30

31 Our study has several limitations that should be highlighted. As discussed earlier, the
32 PCSK9 overexpression model does not perfectly mirror the abnormalities observed in the
33 PCSK9 deficiency models, notably regarding the regulation of DACT2 and TGFBR1. Direct
34 evidence that PCSK9 regulates cell proliferation exclusively in a NODAL-dependent manner

1 is missing. The co-immunoprecipitation experiments with DACT2 were performed with
2 overexpressed PCSK9-V5 constructs and not with endogenous PCSK9. Finally, some hiPSCs
3 lines carry a CNV in the 20th chromosome. Noticeably, all the target genes analyzed in the
4 present study are not located in this genomic area, especially those of the NODAL signaling
5 pathway.

6
7 In conclusion, our study highlights a new function for PCSK9 in hiPSCs proliferation
8 potentially through the modulation of the NODAL signaling pathway. These findings open up
9 new perspectives on the potential link between PCSK9 and embryonic development and/or
10 cancer progression or development. Since there are currently some reflections about the
11 potency of therapeutic PCSK9 inhibition using genomic editing approaches (Musunuru et al.,
12 2021), it is critical to have a clear understanding of PCSK9 biology to avoid potential long-
13 term side effects.

1 **EXPERIMENTAL PROCEDURES**

2 **Ethic statement**

3 The study was conducted in compliance with current Good Clinical Practice standards and in
4 accordance with the principles set forth under the Declaration of Helsinki (1989). Each
5 subject entering the study agreed to and signed an institutional review board-approved
6 statement of informed consent for the collection of urine samples (authorization number from
7 the French Ministry of Health: DC-2011-1399).

8 **Human iPSCs culture and differentiation**

9 *hiPSCs culture.*

10 Reprogramming and characterization of the hiPSC lines were described in previous
11 publications (Si-Tayeb et al., 2010, 2016), see **Supplemental Table 1** for further information
12 on cell lines. HiPSCs were cultured on plates coated with Matrigel (Corning; 0.05 mg/ml) in
13 StemMACS iPS-Brew medium (Miltenyi) and passages were performed using the Gentle Cell
14 Dissociation Buffer (Stem Cell Technologies). Genomic integrity of hiPSC lines was tested
15 using digital PCR of copy number variants (CNVs) of the main human recurrent genomic
16 abnormalities (Stemgenomics, Montpellier, France), see **supplemental Table 1** and
17 supplemental data for CNVs reports. Briefly, all cell lines tested had a good quality control
18 with no CNVs measured except for the PCSK9-FULL overexpression cell line and both K3
19 sh-control and sh-PCSK9 which carry a gain in the 20th chromosome.

20 *hiPSCs differentiation into HLCs*

21 hiPSCs-control were differentiated into HLCs as previously described (Si-Tayeb et al., 2016)
22 in triplicates. Briefly, once cells reach ~70-80% confluency, hiPSCs were cultured in RPMI
23 1640 medium (Life Technologies) supplemented with B27 (with insulin) (Life Technologies),
24 Activin A 100 ng/ml (Miltenyi), FGF2 20 ng/ml (Miltenyi) and BMP4 10 ng/ml (Miltenyi)
25 for 2 days in normoxia (20% O₂, 5% CO₂), then switched to RPMI 1640 with Activin A 100
26 ng/ml for three days to induce definitive endoderm cells (DE). DE cells were further
27 differentiated into hepatic progenitor cells for 5 days in RPMI supplemented with BMP4 20
28 ng/ml and FGF2 10 ng/ml in hypoxia (4% O₂, 5% CO₂). Then cells were cultured for 5 days
29 into immature hepatocytes in RPMI 1640 supplemented with HGF 20 ng/ml (Miltenyi) in
30 hypoxia (4% O₂, 5% CO₂). Then, cells were directed into mature hepatocytes being cultured
31 in hepatocyte culture medium (HCM) (Lonza) supplemented with Oncostatin M 20 ng/ml
32 (Miltenyi) for additional 5-6 days in normoxia (20% O₂, 5% CO₂). RNA samples were
33 collected at every day of the differentiation (day 0 to day 20) and processed further for
34 Quantitative Polymerase Chain Reaction (qPCR) (detailed explanation is shown in the gene

1 expression analysis). 24h conditioned medium was collected, centrifuged then kept for further
2 secretion study using an ELISA assay kit.

3 *Recombinant proteins and chemical treatments*

4 Undifferentiated hiPSCs were treated for 2 hours with recombinant Nodal (R&D, 3218-ND-
5 025) at concentrations ranging from 10 to 200ng/mL in StemMACS iPS-Brew medium
6 without supplements (Miltenyi).

7 Undifferentiated hiPSCs were treated for 24 hours with the wild type PCSK9 recombinant
8 protein (rPCSK9-WT; Circulex, CY-R2330) or the gain of function D374Y-PCSK9
9 recombinant protein (rPCSK9 D374Y (Circulex, CY-R2311) at concentration of 600ng/mL in
10 the routinely used hiPSC culture medium, for each recombinant protein.

11 **Transcriptomic analysis**

12 RNA samples were prepared and hybridized on Agilent Human Gene Expression 8×60 K
13 microarrays (Agilent Technologies, part number: G4851A). Normalization procedures were
14 performed using R statistical software (<http://www.r-project.org>). The raw signals of all
15 probes for all the arrays were normalized against a virtual median array (median raw intensity
16 per row) using a local weighted scattered plot smoother analysis (LOWESS). The data were
17 filtered to remove probes with low intensity values. This filtering is performed by sample
18 category in order to keep the signature of categories with a small sample size. A hierarchical
19 clustering was computed on median-gene-centered and log-transformed data using average
20 linkage and uncentered correlation distances with the Cluster program. We ran a Gene
21 Ontology analysis on differentially expressed genes in order to identify biological processes
22 overrepresented using the PANTHER Overrepresentation test (PANTHER version 16.0 -
23 Released 20210224) (Mi et al., 2021).

24 **Gene expression analysis**

25 RNA samples were isolated using the RNeasy Mini Kit (Qiagen). Reverse transcription of
26 1µg of RNA into cDNA was conducted using the high-capacity cDNA reverse-transcription
27 kit (Applied Biosystems). Conditions were as follows: 10 min at 25°C, and then 2 hours at
28 37°C. Quantitative Polymerase Chain Reaction (qPCR) studies were conducted in triplicate
29 using the brilliant III Ultra-Fast Master Mix with high ROX (Agilent). Primers sequences are
30 listed in *supplemental Table 4*. Each qPCR included 2 s at 50°C, 10 s at 95°C followed by 40
31 cycles of 15 s at 95°C, and 60 s at 60°C. Cycle threshold was calculated by using default
32 settings for the real time sequence detection software (Applied Biosystems).

33 **Protein expression analysis**

1 hiPSCs were lysed in modified RIPA buffer composed of 150 mM NaCl, 50 mM Tris HCl pH
2 8, 1% NP-40 (Nonidet P-40) and 0,1% SDS at pH 7.4 and containing a cocktail of protease
3 inhibitors (Sigma Aldrich) and phosphatase inhibitors (Sigma Aldrich). Total cell lysates were
4 then passed 10 times through a fine gauge needle followed by sonication (5 pulses for 5 sec
5 each). A protein assay was then carried out against a range of standard bovine serum albumin
6 (BSA) using Pierce™ BCA Protein Assay Kit. The lysates were denatured for 10 min at 70
7 °C in a mixture of NuPAGE® Sample Reducing Agent (10X) that contains dithiothreitol
8 (DTT) (500 mM) and NuPAGE® LDS Sample Buffer (4X) containing 2% LDS (lithium
9 dodecyl sulfate), 10% glycerol, 141 mM Tris Base, 106 mM Tris HCl, 0.51 mM EDTA, 0.51
10 mM EDTA, 0.175 mM Phenol Red and pH 8.5. 25 micrograms of each sample were loaded
11 onto a 10% polyacrylamide gel or onto a Bis-Tris NuPAGE™ Novex™ 4 to 12 %
12 (Invitrogen) and the proteins were separated by electrophoresis in presence of SDS. After
13 migration, the proteins are transferred to nitrocellulose membrane (Bio-Rad) using Trans-Blot
14 Turbo Transfer System (Bio-Rad). Revelation and quantification were done by Image Lab
15 software (Bio-Rad). The membrane was saturated for one hour in TBS-T buffer (10 mM Tris,
16 NaCl 0.5 mM and 0.1% Tween-20) containing 5% skimmed milk lyophilized. The membrane
17 was then incubated with primary antibody overnight at 4°C in TBS-T milk. Horseradish
18 peroxidase (HRP)-conjugated secondary antibody staining was performed for 1 h at room
19 temperature (RT) in TBS-T milk. Protein bands were detected using ECL detection system
20 (Bio-Rad) and ECL Clarity max (Ref) when required. Antibody references and dilutions are
21 listed in **supplemental Table 5**.

22 **PCSK9 ELISA assay**

23 PCSK9 levels in conditioned medium were assayed in duplicates using a commercially
24 available quantitative sandwich ELISA assay following the manufacturer's instructions
25 (Circulex CY-8079, CycLex Co.).

26 **PCSK9 silencing in hiPSCs**

27 PCSK9 gene expression has been silenced upon lentiviral transduction of specific shRNA
28 (Sigma). The clone TRCN0000075236 cloned into the pLKO.1-Puro vector has been used to
29 target PCSK9 while an unspecific shRNA sequence has been used as control. Upon
30 transduction, K3 hiPSCs (Si-Tayeb et al., 2010) were subjected to Puromycin (TOCRIS
31 Bioscience 4089/50) selection using a concentration up to 8µg/ml.

32 PCSK9 knockout in control hiPS cells was generated using the Alt-R™ CRISPR-Cas9
33 System (Integrated DNA Technologies) targeting the exon 7 of PCSK9 at both alleles. Briefly
34 gRNA CCAGCGACTGCAGCACCTGC was first duplexed with the Alt-R® CRISPR-Cas9

1 tracrRNA, then complexed to the Alt-R® S.p. Cas9 Nuclease according to IDT
2 recommendations. The complex was delivered into control hiPSCs previously generated (Si-
3 Tayeb et al., 2016) using Amaxa nucleofection (Lonza) and hiPSCs were cultured on mouse
4 embryonic fibroblasts (MEFs) in hiPSCs medium composed of DMEM/F12 (Life
5 Technologies) supplemented with 20% Knockout Serum Replacer (Life Technologies), 0.5%
6 L-Glutamine (Life Technologies) with 0.14% β -mercaptoethanol (Sigma), 1% NEAA and 5
7 ng/ml fibroblast growth factor 2 (FGF2, Miltenyi) in hypoxia (4% O₂, 5% CO₂). Colonies
8 were manually picked from MEFs for cloning strategy then cultured in 96 wells plates under
9 feeder free culture conditions as described earlier. Genotyping of engineered nuclease-
10 induced mutations was performed using T7 endonuclease assay (NEB) followed by PCR
11 sequencing.

12 **Plasmid constructs and hiPS cell lines selection**

13 The TGF- β sensitive promoter upstream the luciferase coding sequence or the sequence
14 coding for FL-PCSK9, L455X and CHR1 were inserted in the AAVS1 site located in
15 chromosome 19 of hiPSCs control and in hiPSCs carrying the *PCSK9* R104C/V114A LOF
16 variant for the luciferase construct only. Briefly, the luciferase construct has been removed
17 from the 3TP-lux plasmid (Addgene #11767) while sequence of FL-PCSK9, L455X and
18 CHR1 were removed from the p-IRES2-EGFP plasmids kindly given by Prof Nabil Seidah's
19 laboratory (Nassoury et al., 2007). Removed sequences were sub-cloned in the AAVS1-
20 hPGK-Puro-PA donor (Addgene #22072). Specific AAVS1 insertion has been performed upon
21 nucleofection (Amaxa, Lonza) of the new construct together with plasmids encoding for
22 hAAVS1 1R TALEN (Addgene #35432) and hAAVS1 1L TALEN (Addgene #35431)
23 homologous sequences as previously described (Hockemeyer et al., 2011). Thereafter, hiPSCs
24 were selected with Puromycin (TOCRIS Bioscience 4089/50; up to 8 μ g/ml) and correct
25 construction insertion has been verified by PCR sequencing

26 **Co-Immunoprecipitation of V5-PCSK9 constructs**

27 The co-Immunoprecipitation (co-IP) was carried out using the magnetic Dynabeads® Protein
28 G immunoprecipitation kit (Life technologies). 50 μ l of Dynabeads were conjugated with 2
29 μ g of V5 antibody (sc-81594) or IgG control (sc-3877) and incubated at RT for 10 min with
30 rotation. The beads were washed three times in 200 μ l lysis buffer and then incubated with
31 500 μ g of total lysates at +4 °C for 2 hours with rotation. Supernatant was then discarded and
32 the beads were washed three times in 200 μ l lysis buffer + Tween 0.05% at +4 °C. Beads-
33 protein complexes are then heated for 10 min at 70 °C in 30 μ l of a mixture of the NuPAGE®
34 Sample Reducing Agent (10X) and LDS Sample Buffer (4X). The samples were placed on

1 the magnet and the attached protein/protein complexes were collected and loaded onto a Bis-
2 Tris NuPAGE™ Novex™ 4 to 12 % (Invitrogen). 25 µg of protein were used as an input.

3 **Biotinylation assay**

4 Cells were washed 2 times with 2 mL ice-cold 1X PBS with calcium and magnesium (Sigma-
5 Aldrich, D8662). Cells were incubated with 1 ml previously dissolve Sulfo-NHS-SS-biotin
6 (Pierce, #21331) in iPS Brew Media (Miltenyi, 130-104-368) to final concentration 0.5mg/ml
7 and agitate 30 min in ice. Biotin solution was discarded and cells were washed 4 times with 2
8 ml Tris-saline solution (10mM Tris-HCl, pH 7.5, 120mM NaCl). 150 µl of lysis buffer were
9 added on cells, scrape, triturate, rotate for 15 min at 4°C and centrifuge 3000 rpm for 10 min
10 at +4°C. Biotinylated proteins were added (1mg) to 100µl Immobilized NeutrAvidin beads
11 (Pierce, #29200) previously wash 2 times with lysis buffer. Incubate with rotation for 2 hours
12 at +4°C. Beads were washed 3 times with 1ml lysis buffer (centrifugation 2500 rpm for
13 30sec) and were eluted with 70 µl 1X SDS sample buffer (Invitrogen, NP0007) + 100 mM
14 DTT at 50°C for 30 min.

15 **Luciferase assay**

16 Basal luciferase activity was detected with the Luciferase Assay System (Promega) by
17 following the manufacturer's instructions. Briefly, 106 cells were plated per well of a 6-well-
18 plate, and cultured overnight at 37°C, 5% CO₂, 4% O₂. Cells were then washed twice and
19 incubated with a specific lysis buffer before freezed at -20 °C for 30 min. Once thawed, the
20 cell lysate was centrifuged and the luciferase assay was performed on the supernatant.
21 Luminescence at 10sec was measured using Perkin Elmer VICTOR™ X3 Multilabel Plate
22 Reader.

23 **Proliferation assay**

24 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium assay was
25 used to assess the proliferation of hiPSCs. Briefly, hiPSCs were plated onto 96-well-plates
26 previously coated with Matrigel 0.05 mg/ml in quintuplicates at 2,500 cells/well with ROCK
27 inhibitor (0.01M, CellGuidance). The day after the passage and the third day, media was
28 changed and supplemented with puromycin for the shRNA-expressing cells (TOCRIS
29 Bioscience, 8 µg/ml). Cells were then incubated for 3h at 37°C with MTT solution (Sigma
30 Aldrich M5655) at 0,8mg/mL in culture medium. The resulting purple-colored formazan
31 crystals were then solubilized using DMSO. Finally, the absorbance was read at 540 nm using
32 Perkin Elmer VICTOR™ X3 Multilabel Plate Reader or VARIOSKAN LUX
33 (Thermoscientific). The proliferation rate was monitored over 24hrs, 48h, 72h and 96h.

34 **Statistical analysis**

1 Data are expressed as mean \pm s.e.m. Significant differences between mean values were
2 determined with the Mann–Whitney U-test for comparison of two groups or paired Student’s
3 t-test if appropriate. For the cluster approach, genes belonging to the same biological function
4 or cell type are known to exhibit correlated expression. We use hierarchical clustering to
5 detect groups of correlated genes supported by a statistical method (limma) to detect
6 differential expression among biological conditions.

7

8 **DATA AND CODE AVAILABILITY**

9

10 Metadata, raw and normalized data have been deposited in the Gene Expression Omnibus
11 database (GSE181610, <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE181610>).

12

1 **ACKNOWLEDGMENTS**

2 This study was supported by a grant from the Fondation Leducq (#13CVD03); the foundation
3 GENAVIE; and the French national research project CHOPIN (CHolesterol Personalized
4 INnovation) funded by the Agence Nationale de la Recherche (ANR-16-RHUS-0007) and
5 coordinated by the CHU of Nantes., the VaCaRMe project funded by the Région Pays de la
6 Loire, the CHU of Nantes, the Lebanese University President grant and a CIFRE grant funded
7 by HCS Pharma.

8 We are most grateful to the Bioinformatics Core Facility of Nantes BiRD, member of
9 Biogenouest, Institut Français de Bioinformatique (IFB) (ANR-11-INBS-0013) for the use of
10 its resources and for its technical support. AR is supported by post-doctoral fellowship grants
11 from the “Fondation Recherche Médicale” and from the “Institut de France-Fondation
12 Lefoulon-Delalande”.

13

14 **AUTHOR CONTRIBUTIONS**

15 M.R., S.I., A.C., B.C., and K.S-T. designed the experiments. M.R., S.I., A.C., A.G., B.C.,
16 A.D., A.L., L.A., M.P., A.P. and N.G.S. performed the experiments. M.R., S.I, A.C., A.G,
17 A.R, B.C., K.S-T. analyzed the data. M.R., S.I., A.C, A.G, C.L-M., K.Z., B.C. and K.S-T
18 wrote the paper. A.R., X.P. C.L-M. contributed to the discussion. B.C. supported the work of
19 M.R., A.C., A.G., B.C., A.D., A.L. and K.S-T. K.Z., supported the work of S.I. K.S-T
20 conceived the project.

21

22 **DECLARATION OF INTERESTS**

23 B.C. has received research funding from Amgen, Pfizer and Sanofi and Regeneron
24 Pharmaceuticals Inc outside of the present work; and has served on scientific advisory boards
25 and received honoraria or consulting fees from Amgen, Regeneron and Sanofi. The other
26 authors declare no conflict of interest.

1 REFERENCES

- 2 Abifadel, M., Varret, M., Rabès, J.P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C.,
3 Benjannet, S., Wickham, L., Erlichje vais 4–156.
- 4 Almeida, C.R., Ferreira, B.H., and Duarte, I.F. (2021). Targeting PCSK9: a promising
5 adjuvant strategy in cancer immunotherapy. *Sig Transduct Target Ther* 6, 111.
- 6 An, D., Wei, X., Li, H., Gu, H., Huang, T., Zhao, G., Liu, B., Wang, W., Chen, L., Ma, W., et
7 al. (2015). Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of
8 neural tube defects using iTRAQ quantitative proteomics. *Scientific Reports* 5, 17559.
- 9 Assou, S., Le Carrou, T., Tondeur, S., Ström, S., Gabelle, A., Marty, S., Nadal, L., Pantesco,
10 V., Réme, T., Hugnot, J.-P., et al. (2007). A meta-analysis of human embryonic stem cells
11 transcriptome integrated into a web-based expression atlas. *Stem Cells* 25, 961–973.
- 12 Benjannet, S., Rhainds, D., Essalmani, R., Mayne, J., Wickham, L., Jin, W., Asselin, M.-C.,
13 Hamelin, J., Varret, M., Allard, D., et al. (2004). NARC-1/PCSK9 and its natural mutants:
14 zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL
15 cholesterol. *The Journal of Biological Chemistry* 279, 48865–48875.
- 16 Calloni, R., Cordero, E.A.A., Henriques, J.A.P., and Bonatto, D. (2013). Reviewing and
17 updating the major molecular markers for stem cells. *Stem Cells Dev* 22, 1455–1476.
- 18 Cariou, B., Ouguerram, K., Zaïr, Y., Guerois, R., Langhi, C., Kourimate, S., Benoit, I., Le
19 May, C., Gayet, C., Belabbas, K., et al. (2009). PCSK9 dominant negative mutant results in
20 increased LDL catabolic rate and familial hypobetalipoproteinemia. *Arteriosclerosis,
21 Thrombosis, and Vascular Biology* 29, 2191–2197.
- 22 Cariou, B., Si-Tayeba, K., and Le Maya, C. (2015). Role of PCSK9 beyond liver
23 involvement. *Current Opinion in Pediatrics* 26, 155–161.
- 24 Catapano, A.L., Pirillo, A., and Norata, G.D. (2020). New Pharmacological Approaches to
25 Target PCSK9. *Current Atherosclerosis Reports* 22.
- 26 Chetty, B.N.R., Waxman, J.S., Miller, J.R., Takemaru, K.I., Sheldahl, L.C., Khlebtsova, N.,
27 Fox, E.P., Earnest, T., and Moon, R.T. (2002). Dapper, a Dishevelled-associated antagonist of
28 β -catenin and JNK signaling, is required for notochord formation. *Developmental Cell* 2,
29 449–461.
- 30 Chng, Z., Teo, A., Pedersen, R.A., and Vallier, L. (2010). SIP1 Mediates Cell-Fate Decisions
31 between Neuroectoderm and Mesendoderm in Human Pluripotent Stem Cells. *Cell Stem Cell*
32 6, 59–70.
- 33 Cohen, J.C., Boerwinkle, E., Mosley, T.H., and Hobbs, H.H. (2006). Sequence variations in
34 PCSK9, low LDL, and protection against coronary heart disease. *New England Journal of
35 Medicine* 354, 1264–1272.
- 36 Ference, B.A., Robinson, J.G., Brook, R.D., Catapano, A.L., Chapman, M.J., Neff, D.R.,
37 Voros, S., Giugliano, R.P., Davey Smith, G., Fazio, S., et al. (2016). Variation in *PCSK9* and
38 *HMGCR* and Risk of Cardiovascular Disease and Diabetes. *New England Journal of
39 Medicine* 375, 2144–2153.
- 40 Gonsar, N., Coughlin, A., Clay-Wright, J.A., Borg, B.R., Kindt, L.M., and Liang, J.O. (2016).
41 Temporal and spatial requirements for Nodal-induced anterior mesendoderm and mesoderm
42 in anterior neurulation. *Genesis* 54, 3–18.
- 43 Hockemeyer, D., Wang, H., Kiani, S., Lai, C.S., Gao, Q., Cassady, J.P., Cost, G.J., Zhang, L.,
44 Santiago, Y., Miller, J.C., et al. (2011). Genetic engineering of human pluripotent cells using
45 TALE nucleases. *Nat Biotechnol* 29, 731–734.
- 46 Huang, J., Li, L., Lian, J., Schauer, S., Vesely, P.W., Kratky, D., Hoefler, G., and Lehner, R.
47 (2016). Tumor-Induced Hyperlipidemia Contributes to Tumor Growth. *Cell Reports* 15, 336–
48 348.
- 49 Huang, T., David, L., Mendoza, V., Yang, Y., Villarreal, M., De, K., Sun, L., Fang, X.,
50 López-Casillas, F., Wrana, J.L., et al. (2011). TGF- β signalling is mediated by two

1 autonomously functioning TβRI:TβRII pairs. *EMBO Journal* 30, 1263–1276.

2 James, D., Levine, A.J., Besser, D., and Hemmati-Brivanlou, A. (2005).

3 TGFβ/activin/nodal signaling is necessary for the maintenance of pluripotency in human

4 embryonic stem cells. *Development* 132, 1273–1282.

5 Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., and Li,

6 C.-Y. (2020). Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. *Nature*

7 588, 693–698.

8 Maxwell, K.N., and Breslow, J.L. (2004). Adenoviral-mediated expression of Pcsk9 in mice

9 results in a low-density lipoprotein receptor knockout phenotype. *Proceedings of the National*

10 *Academy of Sciences of the United States of America* 101, 7100–7105.

11 Mi, H., Ebert, D., Muruganujan, A., Mills, C., Albu, L.-P., Mushayamaha, T., and Thomas,

12 P.D. (2021). PANTHER version 16: a revised family classification, tree-based classification

13 tool, enhancer regions and extensive API. *Nucleic Acids Research* 49, D394–D403.

14 Musunuru, K., Chadwick, A.C., Mizoguchi, T., Garcia, S.P., DeNizio, J.E., Reiss, C.W.,

15 Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021). In vivo CRISPR base editing of

16 PCSK9 durably lowers cholesterol in primates. *Nature* 593, 429–434.

17 Nassoury, N., Blasiolo, D.A., Tebon Oler, A., Benjannet, S., Hamelin, J., Poupon, V.,

18 McPherson, P.S., Attie, A.D., Prat, A., and Seidah, N.G. (2007). The Cellular Trafficking of

19 the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR. *Traffic* 8,

20 718–732.

21 Pauklin, S., and Vallier, L. (2015). Activin/Nodal signalling in stem cells. *Development* 142,

22 607–619.

23 Poirier, S., Mayer, G., Poupon, V., McPherson, P.S., Desjardins, R., Ly, K., Asselin, M.C.,

24 Dy, R., Duclos, F.J., Witmer, M., et al. (2009). Dissection of the endogenous cellular

25 pathways of PCSK9-induced low density Lipoprotein receptor degradation. Evidence for an

26 intracellular route. *Journal of Biological Chemistry* 284, 28856–28864.

27 Preiss, D., Tobert, J.A., Hovingh, G.K., and Reith, C. (2020). Lipid-Modifying Agents, From

28 Statins to PCSK9 Inhibitors: JACC Focus Seminar. *Journal of the American College of*

29 *Cardiology* 75, 1945–1955.

30 Rabadán, M.A., Herrera, A., Fanlo, L., Usieto, S., Carmona-Fontaine, C., Barriga, E.H.,

31 Mayor, R., Pons, S., and Martí, E. (2016). Delamination of neural crest cells requires transient

32 and reversible Wnt inhibition mediated by Dact1/2. *Development (Cambridge)* 143, 2194–

33 2205.

34 Rashid, S., Curtis, D.E., Garuti, R., Anderson, N.H., Bashmakov, Y., Ho, Y.K., Hammer,

35 R.E., Moon, Y.A., and Horton, J.D. (2005). Decreased plasma cholesterol and

36 hypersensitivity to statins in mice lacking Pcsk9. *Proceedings of the National Academy of*

37 *Sciences of the United States of America* 102, 5374–5379.

38 Seidah, N.G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Bélanger Jasmin, S., Stifani, S.,

39 Basak, A., Prat, A., Chrétien, M., Jasmin, S.B., et al. (2003). The secretory proprotein

40 convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and

41 neuronal differentiation. *100*, 928–933.

42 Seidah, N.G., Abifadel, M., Prost, S., Boileau, C., and Prat, A. (2017). The proprotein

43 convertases in hypercholesterolemia and cardiovascular diseases: Emphasis on proprotein

44 convertase subtilisin/Kexin 9. *Pharmacological Reviews* 69, 33–52.

45 Si-Tayeb, K., Noto, F.K., Sepac, A., Sedlic, F., Bosnjak, Z.J., Lough, J.W., and Duncan, S.A.

46 (2010). Generation of human induced pluripotent stem cells by simple transient transfection

47 of plasmid DNA encoding reprogramming factors. *BMC Developmental Biology* 10, 81.

48 Si-Tayeb, K., Idriss, S., Champon, B., Caillaud, A., Pichelin, M., Arnaud, L., Lemarchand, P.,

49 Le May, C., Zibara, K., and Cariou, B. (2016). Urine-sample-derived human induced

50 pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant

1 hypercholesterolemia. *Disease Models & Mechanisms* 9, 81–90.

2 Stoekenbroek, R.M., Lambert, G., Cariou, B., and Hovingh, G.K. (2018). Inhibiting PCSK9 -
3 biology beyond LDL control. *Nat Rev Endocrinol* 15, 52–62.

4 Su, Y., Zhang, L., Gao, X., Meng, F., Wen, J., Zhou, H., Meng, A., and Chen, Y. (2007). The
5 evolutionally conserved activity of Dapper2 in antagonizing TGF- β signaling. *The FASEB*
6 *Journal* 21, 682–690.

7 Sun, X., Essalmani, R., Day, R., Khatib, A.M., Seidah, N.G., and Prat, A. (2012). Proprotein
8 convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. *Neoplasia*
9 (United States) 14, 1122–1131.

10 Topczewska, J.M., Postovit, L.M., Margaryan, N. V., Sam, A., Hess, A.R., Wheaton, W.W.,
11 Nickoloff, B.J., Topczewski, J., and Hendrix, M.J.C. (2006). Embryonic and tumorigenic
12 pathways converge via Nodal signaling: Role in melanoma aggressiveness. *Nature Medicine*
13 12, 925–932.

14 Tsuneyoshi, N., Sumi, T., Onda, H., Nojima, H., Nakatsuji, N., and Suemori, H. (2008).
15 PRDM14 suppresses expression of differentiation marker genes in human embryonic stem
16 cells. *Biochem Biophys Res Commun* 367, 899–905.

17 Vallier, L., Mendjan, S., Brown, S., Chng, Z., Teo, A., Smithers, L.E., Trotter, M.W.B.B.,
18 Cho, C.H.H.H.-H., Martinez, A., Rugg-Gunn, P., et al. (2009). Activin/Nodal signalling
19 maintains pluripotency by controlling Nanog expression. *Development* 136, 1339–1349.

20 Zhang, D.W., Lagace, T.A., Garuti, R., Zhao, Z., McDonald, M., Horton, J.D., Cohen, J.C.,
21 and Hobbs, H.H. (2007). Binding of proprotein convertase subtilisin/kexin type 9 to
22 epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor
23 recycling and increases degradation. *Journal of Biological Chemistry* 282, 18602–18612.

24 Zhang, L., Zhou, H., Su, Y., Sun, Z., Zhang, H., Zhang, L., Zhang, Y., Ning, Y., Chen, Y.G.,
25 and Meng, A. (2004). Zebrafish Dpr2 inhibits mesoderm induction by promoting degradation
26 of nodal receptors. *Science* 306, 114–117.

27 Zhao, Z., Tuakli-Wosornu, Y., Lagace, T.A., Kinch, L., Grishin, N. V., Horton, J.D., Cohen,
28 J.C., and Hobbs, H.H. (2006). Molecular characterization of loss-of-function mutations in
29 PCSK9 and identification of a compound heterozygote. *American Journal of Human Genetics*
30 79, 514–523.

31

1 **FIGURE TITLES AND LEGENDS**

2

3 **Figure 1. PCSK9 is highly expressed in undifferentiated hiPSCs.** **A.** Daily PCSK9 mRNA
4 expression throughout hiPSC differentiation into HLCs (n=3 independent differentiations). **B.**
5 Left Panel, PCSK9 protein expression quantification by western blot analysis in hiPSCs and
6 hepatic progenitor cell lysates (n=3 independent differentiations). Right panel, western blot
7 quantifications upon β -actin normalization. **C.** Secreted PCSK9 protein quantification in cell
8 culture supernatant by ELISA assay at day 0, 5, 10, 15 and 20 of HLCs differentiation (n=3
9 independent differentiations), ** p value <0.01.

10

11 **Figure 2. PCSK9 inhibition impairs *NODAL* gene expression and hiPSCs proliferation.**
12 **A.** Q-PCR analysis expression of *PCSK9*, *LDLR*, *NODAL*, *LEFTY1*, *NANOG*, *OCT3/4* and
13 *SOX2* in hiPSCs expressing a control shRNA or directed against PCSK9 (n=3 different hiPSC
14 passages). **B.** Cell growth of hiPSCs expressing a control shRNA compared to a shRNA
15 directed against PCSK9 (n=4 independent experiments), * p value <0.05.

16

17 **Figure 3. hiPSCs proliferation and SMAD2 phosphorylation status are modulated by**
18 **PCSK9 inhibition or overexpression.** **A.** Left Panel, PCSK9 protein expression
19 quantification by western blot analysis in hiPSCs knock out (n=9: 3 passages of 3 different
20 hiPSC clones) and hiPSCs overexpressing PCSK9-FULL (n=3 different hiPSC passages).
21 Right panel, western blot quantifications upon α -tubulin normalization. **B.** Cell growth of
22 hiPSCs control compared to a knocked out for PCSK9 and hiPSCs overexpressing PCSK9-
23 FULL (respectively, n=4 and n=3 independent experiments). **C.** Left Panel, P-SMAD2 and
24 total SMAD2 detection by western blot in hiPSCs knockout for PCSK9 (n=9: 3 passages of 3
25 different hiPS clones) or overexpressing PCSK9-FULL (n=3 different passages) compared to
26 hiPSCs control (n=3 different passages). Right panel, western blot quantification analyzed on
27 the ratio P-SMAD2/total SMAD2/ α -tubulin), * p value <0.05, ** p value <0.01.

28

29 **Figure 4. PCSK9 loss of function mutations R104C/V114A inhibit hiPS cell proliferation**
30 **and decrease SMAD2 phosphorylation.** **A.** Western blot directed against PCSK9 and β -
31 actin in hiPSCs control (n=3 different passages) and R104C/V114A (n=3 different passages)
32 **B.** Cell growth of hiPSCs control compared to hiPSCs carrying the PCSK9-R104C/V114A
33 mutations (n=4 independent experiments). **C.** Left Panel, P-SMAD2 and total SMAD2
34 detection by western blot in hiPSCs control (n=3 different passages) and R104C/V114A (n=3

1 different passages). Right panel, western blot quantification analyzed on the ratio P-
2 SMAD2/T-SMAD2/ α -tubulin. **D.** TGF β -promoter activity detection by luciferase assay in
3 control hiPSCs (n=3 different passages) and hiPSCs carrying the R104C/V114A mutations
4 (n=3 different passages). * p value <0.05, *** p value <0.001.

5

6 **Figure 5. PCSK9 regulates the abundance of the TGF β R1 at the cell membrane. A.**

7 Protein detection by western blot of the transferrin receptor, the TGF β -R1 receptor and
8 GAPDH in hiPSCs total lysate (left panel) or at the cell membrane upon biotinylation assay
9 (middle panel) quantified as a ratio of TGF β -R1/Transferrin receptor (right panel). * p value <
10 0,05

11

12 **Figure 6. PCSK9 is acting intracellularly through DACT2. A.** Left panel, DACT2

13 detection by western blot in control (n=3 different passages), PCSK9-KO (n=9, 3 passages of
14 3 different hiPSC clones) hiPS cell lines. Right panel, western blot quantifications upon α -
15 tubulin normalization; **B.** Left panel, DACT2 detection by western blot in control (n=3
16 different passages) and PCSK9-R104C/V114A (n=3 different passages) hiPS cell lines. Right
17 panel, western blot quantifications upon α -tubulin normalization; **C.** Left panel, DACT2
18 detection by western blot in control (n=3 different passages) and PCSK9-FULL
19 overexpression (n=3 different passages) hiPS cell lines. Right panel, western blot
20 quantifications upon α -tubulin normalization; * p value <0.05, ns: non-significant.

21

22 **Figure 7. PCSK9 is interacting with DACT2 through its CHR domain. A.** Diagram

23 picturing the different V5-PCSK9 constructs tested. **B.** V5-PCSK9 and DACT2 detection by
24 western blot upon V5 co-immunoprecipitation in cellular lysate of hiPS cells expressing the
25 FULL-PCSK9, L455X or CHR domain construct. Immunoglobulin (Ig) was used as a negative
26 control while V5 directed antibody was to pull down FULL-PCSK9, L455X or CHR.

27








Figure 1

A**B****Figure 2**




Figure 3




Figure 4




Figure 5





Figure 6

A



B




Figure 7